Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Timber Pharmaceuticals, Inc. | v468224_ex99-1v2.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: June 1, 2017
(Date of earliest event reported)
BIOPHARMX CORPORATION
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 001-37411 | 59-3843182 | |
| (Commission File Number) | (IRS Employer Identification No.) |
|
1505 Adams Drive, Suite D Menlo Park, California |
94025 | |
| (Address of Principal Executive Offices) | (Zip Code) |
(650) 889-5020
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
| Emerging growth company | ¨ | ||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ¨ | ||
| Item 7.01. | Regulation FD Disclosure. |
On June 1, 2017, BioPharmX Corporation (the “Company”) issued a press release announcing comprehensive results from the Company’s phase 2b clinical trial evaluating its product candidate BPX-01, a hydrophilic topical minocycline gel product candidate for the treatment of moderate-to-severe acne. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference. The Company also presented these results at a “State of Acne” symposium in New York City on June 1, 2017. The event was webcast live and the event and presentation materials will be archived for 90 days at http://www.biopharmx.com/media/#events.
The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits |
(d)
| Exhibit No. | Description |
| 99.1 | Press Release, dated June 1, 2017 by BioPharmX Corporation |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIOPHARMX CORPORATION | ||
| Date: June 1, 2017 | By: | /s/ Greg Kitchener |
| Name: Title: |
Greg Kitchener Chief Financial Officer | |
EXHIBIT INDEX
| Exhibit No. | Description |
| 99.1 | Press Release, dated June 1, 2017 by BioPharmX Corporation |